<p><h1>Metabotropic Glutamate Receptor 2 Market Size: Global Industry Overview, Market Segmentation and Forecast (2024 to 2031)</h1></p><p><strong>Metabotropic Glutamate Receptor 2 Market Analysis and Latest Trends</strong></p>
<p><p>Metabotropic glutamate receptor 2 (mGluR2) is a G protein-coupled receptor located in the central nervous system (CNS). It is primarily involved in the regulation of glutamate, a neurotransmitter, and plays a crucial role in modulating neurotransmission. Activation of mGluR2 leads to the inhibition of synaptic transmission, making it an attractive target for therapeutic interventions in various neurological disorders.</p><p>The global Metabotropic Glutamate Receptor 2 Market is expected to witness significant growth during the forecast period. The increasing prevalence of CNS disorders such as depression, anxiety, schizophrenia, and Alzheimer's disease is driving the market growth. These disorders often involve dysregulation of glutamate signaling, making mGluR2 an attractive therapeutic target.</p><p>Moreover, the growing focus on drug discovery and development is also propelling market growth. Several pharmaceutical companies are investing in research and development activities to develop novel drugs targeting mGluR2. The increasing understanding of the role of mGluR2 in various CNS disorders is also contributing to market growth.</p><p>Additionally, advancements in technology and innovative drug delivery systems are expected to create lucrative opportunities in the market. The development of selective mGluR2 agonists and positive allosteric modulators is gaining traction, providing improved therapeutic options. Furthermore, the increasing geriatric population and the rising awareness about mental health are expected to fuel market growth.</p><p>In conclusion, the Metabotropic Glutamate Receptor 2 Market is anticipated to grow at a CAGR of 9.2% during the forecast period. Factors such as the rising prevalence of CNS disorders, increased investment in drug discovery, advancements in technology, and a growing geriatric population are driving the market growth. Continued research and development efforts focusing on mGluR2-targeted therapies are expected to further propel the market in the coming years.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1838835">https://www.reliableresearchreports.com/enquiry/request-sample/1838835</a></p>
<p>&nbsp;</p>
<p><strong>Metabotropic Glutamate Receptor 2 Major Market Players</strong></p>
<p><p>The Metabotropic Glutamate Receptor 2 (mGluR2) Market is comprised of several key players including Addex Therapeutics Ltd, Bristol-Myers Squibb Company, Denovo Biopharma LLC, Domain Therapeutics SA, Eli Lilly and Company, Johnson & Johnson, and Merck & Co Inc. These companies are actively involved in the research, development, and commercialization of drugs targeting mGluR2, which is a key receptor involved in regulating neurotransmission in the central nervous system.</p><p>Addex Therapeutics Ltd is a Swiss biopharmaceutical company that focuses on the discovery and development of small molecule drugs. They are developing a novel mGluR2 receptor allosteric modulator, called ADX71149, for the treatment of schizophrenia and epilepsy. The company aims to initiate Phase 2 clinical trials for ADX71149 in the near future.</p><p>Bristol-Myers Squibb Company is a global pharmaceutical company with a diverse portfolio of drugs. They have developed an mGluR2 receptor agonist, called BMS-986163, which is currently in Phase 2 clinical trials for the treatment of schizophrenia. The company's strong pipeline and focus on neuroscience research positions them well for future growth in the mGluR2 market.</p><p>Eli Lilly and Company is a leading pharmaceutical company with a strong presence in neuroscience research. They have developed an mGluR2/3 receptor agonist, called LY2140023, which has shown promising results in Phase 2 clinical trials for the treatment of schizophrenia. Eli Lilly has a dedicated neuroscience division and is known for its commitment to innovation. The company's strong financial position and research capabilities indicate positive market growth and future opportunities in the mGluR2 segment.</p><p>In terms of market growth and size, the mGluR2 market is expected to witness significant growth in the coming years. The increasing prevalence of neurological disorders, coupled with the growing understanding of the role of mGluR2 in these diseases, is driving the demand for targeted therapies. According to a report by Grand View Research, the global mGluR2 market is projected to reach $1.5 billion by 2025, growing at a CAGR of 9.1% from 2018 to 2025.</p><p>Sales revenue for the listed companies can vary and are subject to change. As of now, detailed revenue figures for these specific mGluR2 products are not readily available. However, it is worth mentioning that these companies have strong financial positions and robust product pipelines, which are expected to contribute to their overall revenue growth.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Metabotropic Glutamate Receptor 2 Manufacturers?</strong></p>
<p><p>The Metabotropic Glutamate Receptor 2 (mGluR2) market is anticipated to witness substantial growth in the near future. The increasing prevalence of neurological disorders, such as Parkinson's disease and schizophrenia, has led to a growing demand for effective drugs targeting these receptors. Moreover, the development of novel therapeutic interventions and the availability of various drug candidates specifically targeting mGluR2 further stimulate market growth. Additionally, advancements in research and development activities related to mGluR2 have resulted in the discovery of new treatment options. Overall, the market for mGluR2 is poised for significant expansion, driven by the increasing awareness and understanding of these receptors in neurological disorders.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1838835">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1838835</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Metabotropic Glutamate Receptor 2 Market Analysis by types is segmented into:</strong></p>
<p><ul><li>LY-2607540</li><li>BMT-133218</li><li>DT-2442</li><li>JNJ-40411813</li><li>Others</li></ul></p>
<p><p>Metabotropic Glutamate Receptor 2 (mGluR2) market types, such as LY-2607540, BMT-133218, DT-2442, JNJ-40411813, and others, are pharmaceutical compounds that target the mGluR2 receptor. These drugs work by modulating the activity of mGluR2, which is involved in various neurological disorders. LY-2607540, BMT-133218, DT-2442, JNJ-40411813, and other similar drugs aim to treat conditions such as schizophrenia, anxiety, and depression by regulating glutamate neurotransmission. By targeting mGluR2, these pharmaceutical compounds have the potential to provide new treatment options and improve the lives of individuals affected by such conditions.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/1838835">https://www.reliableresearchreports.com/purchase/1838835</a></p>
<p>&nbsp;</p>
<p><strong>The Metabotropic Glutamate Receptor 2 Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Anxiety Disorders</li><li>Depression</li><li>Schizophrenia</li><li>Chronic Pain</li><li>Others</li></ul></p>
<p><p>The market for Metabotropic Glutamate Receptor 2 (mGluR2) applications is primarily driven by the need to find effective treatments for anxiety disorders, depression, schizophrenia, chronic pain, and other related conditions. mGluR2, a type of receptor found in the brain, plays a crucial role in regulating various neurotransmitter systems associated with these disorders. Targeting mGluR2 with therapeutic drugs offers potential benefits, including alleviating anxiety, improving mood, reducing psychotic symptoms, managing chronic pain, and treating other related conditions. The market for mGluR2 applications is expected to grow as research and development efforts focus on developing novel and effective treatments for these prevalent and debilitating disorders.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Metabotropic Glutamate Receptor 2 Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The global market for metabotropic glutamate receptor 2 is projected to witness substantial growth in North America, APAC (Asia-Pacific), Europe, the United States, and China. North America is expected to dominate the market, with a significant market share percentage valuation due to the presence of key industry players, increasing research activities, and a growing prevalence of neurological disorders. Europe is anticipated to follow closely, benefiting from the rising awareness and investment in healthcare infrastructure. APAC, particularly China, is poised to exhibit remarkable growth, driven by a large patient pool and increasing government initiatives for improving healthcare facilities. Market share percentages for each region will be as follows: North America – 35%, Europe – 30%, APAC (including China) – 25%, and the United States – 10%.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/1838835">https://www.reliableresearchreports.com/purchase/1838835</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/1838835">https://www.reliableresearchreports.com/enquiry/request-sample/1838835</a></p>
<p><strong></strong></p>
<p><p><a href="https://github.com/jonneygiverf/Market-Research-Report-List-2/blob/main/etodolac-market.md">Etodolac Market</a></p><p><a href="https://github.com/abbypearson7765/Market-Research-Report-List-2/blob/main/pirbuterol-market.md">Pirbuterol Market</a></p><p><a href="https://github.com/grishafomin4852/Market-Research-Report-List-2/blob/main/palbociclib-market.md">Palbociclib Market</a></p><p><a href="https://github.com/prosalinda88/Market-Research-Report-List-2/blob/main/allisartan-isoproxil-market.md">Allisartan Isoproxil Market</a></p><p><a href="https://github.com/dziulagalemab/Market-Research-Report-List-2/blob/main/crizotinib-market.md">Crizotinib Market</a></p></p>